Coya Therapeutics, Common Stock Performance
| COYA Stock | 6.21 0.09 1.47% |
On a scale of 0 to 100, Coya Therapeutics, holds a performance score of 3. The firm shows a Beta (market volatility) of 2.3, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Coya Therapeutics, will likely underperform. Please check Coya Therapeutics,'s skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Coya Therapeutics,'s price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Coya Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Coya Therapeutics, sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.77) | Five Day Return 0.33 | Year To Date Return (12.07) | Ten Year Return 33.92 | All Time Return 33.92 |
1 | Coya Therapeutics Earns Buy Rating from Analysts at HC Wainwright | 09/20/2024 |
2 | Coya Therapeutics Announces Closing of 10.0 Million Private Placement | 10/23/2024 |
3 | Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Mo... | 10/28/2024 |
4 | Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 in Alzheimers Disease Presented at the Clinical Tria... | 10/29/2024 |
5 | Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results | 11/06/2024 |
6 | Acquisition by Arun Swaminathan of 5000 shares of Coya Therapeutics, at 7.3378 subject to Rule 16b-3 | 11/11/2024 |
7 | Acquisition by Arun Swaminathan of 5000 shares of Coya Therapeutics, at 7.3594 subject to Rule 16b-3 | 11/13/2024 |
8 | Acquisition by David Snyder of 1800 shares of Coya Therapeutics, at 7.1858 subject to Rule 16b-3 | 11/14/2024 |
9 | Insider Buying CFO David Snyder Acquires Shares of Coya Therapeutics Inc | 11/15/2024 |
10 | Coya Therapeutics files to sell 1.38M shares of common stock for holders - MSN | 11/21/2024 |
11 | Acquisition by David Snyder of 70596 shares of Coya Therapeutics, at 8.15 subject to Rule 16b-3 | 12/03/2024 |
12 | Boral Capital initiates coverage on Coya Therapeutics with Buy rating | 12/04/2024 |
| Begin Period Cash Flow | 5.9 M |
Coya |
Coya Therapeutics, Relative Risk vs. Return Landscape
If you would invest 596.00 in Coya Therapeutics, Common on September 12, 2024 and sell it today you would earn a total of 18.00 from holding Coya Therapeutics, Common or generate 3.02% return on investment over 90 days. Coya Therapeutics, Common is currently generating 0.2298% in daily expected returns and assumes 5.9255% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Coya, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Coya Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Coya Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Coya Therapeutics, Common, and traders can use it to determine the average amount a Coya Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0388
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | COYA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.93 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Coya Therapeutics, is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Coya Therapeutics, by adding it to a well-diversified portfolio.
Coya Therapeutics, Fundamentals Growth
Coya Stock prices reflect investors' perceptions of the future prospects and financial health of Coya Therapeutics,, and Coya Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Coya Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.17) % | ||||
| Current Valuation | 118.07 M | ||||
| Shares Outstanding | 16.71 M | ||||
| Price To Book | 3.19 X | ||||
| Price To Sales | 10.89 X | ||||
| Revenue | 6 M | ||||
| EBITDA | (7.9 M) | ||||
| Net Income | (7.99 M) | ||||
| Total Debt | 5.63 M | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (11.19 M) | ||||
| Earnings Per Share | (0.65) X | ||||
| Market Capitalization | 104.09 M | ||||
| Total Asset | 41.26 M | ||||
| Retained Earnings | (25.86 M) | ||||
| Working Capital | 36.14 M | ||||
About Coya Therapeutics, Performance
By analyzing Coya Therapeutics,'s fundamental ratios, stakeholders can gain valuable insights into Coya Therapeutics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Coya Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Coya Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.22) | (0.21) |
Things to note about Coya Therapeutics, Common performance evaluation
Checking the ongoing alerts about Coya Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Coya Therapeutics, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Coya Therapeutics, had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 6 M. Net Loss for the year was (7.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Coya Therapeutics, generates negative cash flow from operations | |
| Coya Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Boral Capital initiates coverage on Coya Therapeutics with Buy rating |
- Analyzing Coya Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Coya Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Coya Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Coya Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Coya Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Coya Therapeutics,'s stock. These opinions can provide insight into Coya Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Coya Stock analysis
When running Coya Therapeutics,'s price analysis, check to measure Coya Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coya Therapeutics, is operating at the current time. Most of Coya Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Coya Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coya Therapeutics,'s price. Additionally, you may evaluate how the addition of Coya Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |